Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.14874 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Mona Hussein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Migraine Disorders, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
The Migraine‐Specific Quality‐of‐Life Questionnaire version 2.1 (MSQ 2.1) is one of the most frequently used tools in assessing the impact of migraine in clinical practice and in migraine research. This work aimed to examine the reliability and validity of the Arabic version of the MSQ 2.1 in Arabic‐speaking patients with migraine and to assess its ability to detect subtle changes in quality of life after receiving prophylactic migraine medications.
Methods
This multicenter prospective observational study was conducted with 140 patients experiencing migraine and indicated for prophylactic medications. Headache assessment was done at baseline and 3 months after receiving prophylactic medications using the Arabic version of MSQ 2.1, Headache Impact Test (HIT‐6), and visual analog scale (VAS). The MSQ 2.1 was repeated 1 week after the first visit to a group of patients ( n = 70) to assess test–retest reliability.
Results
Cronbach's alpha for the MSQ 2.1 was 0.973, indicating excellent internal consistency. The intraclass correlation coefficient (average measure) was 0.99, indicating excellent test–retest reliability. There were statistically significant correlations between the MSQ 2.1 total score and monthly migraine days, VAS, and HIT‐6 scores before and 3 months after prophylactic medications. The receiver operating characteristic curve revealed that an increase of 8.5 in the total score of the MSQ 2.1 represents the minimally important change that means significant improvement (area under the curve = 0.785, sensitivity = 0.861, specificity = 0.656, p < 0.001).
Conclusion
The Arabic version of the MSQ 2.1 is a valid, reliable, and sensitive tool that can precisely assess the impact of migraine on quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
- Department of Neurology, Cairo University, Cairo, Egypt.
- Department of Public Health and Community Medicine, Beni-Suef University, Beni-Suef, Egypt.
- Department of Anesthesiology, Surgical ICU and Pain Management, Beni-Suef University, Beni-Suef, Egypt.
- Neurology Department, Aseer Central Hospital, Abha, Kingdom of Saudi Arabia.
- Neurology Department, MOH Hera Hospital, Makkah, Kingdom of Saudi Arabia.
ORCID-Profile: Mona Hussein, Mona A F Nada, Rehab Magdy
Zitieren
APA
Hussein, M., Hassan, A., Nada, M. A. F., Mohammed, Z., Fathy, W., Abdel Ghaffar, N. F., Kedah, H., & Magdy, R. (2025). Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14874
Vancouver
Hussein M, Hassan A, Nada MAF, Mohammed Z, Fathy W, Abdel Ghaffar NF, et al. Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14874
BibTeX
@article{Hussein2025,
author = {Hussein, Mona and Hassan, Amr and Nada, Mona A F and Mohammed, Zeinab and Fathy, Wael and Abdel Ghaffar, Nawal F and Kedah, Hanaa and Magdy, Rehab},
title = {Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.14874}
}
EUVIMED